What should I know first?

Alzheimer's disease affects the brain over time and may first become noticeable through difficulties learning or recalling recent information. It is not simply a more severe version of ordinary forgetfulness. The disease and the level of impairment are separate ideas: some people have mild cognitive impairment due to Alzheimer's disease, while others have dementia that interferes with independence.

A diagnosis should describe both the likely cause and its current effect on daily life. This page focuses on Alzheimer's disease rather than using the name as a synonym for every form of cognitive decline.

How Common Is It?

Alzheimer's disease is the most common cause of dementia among older adults. Risk increases with age, but the disease is not inevitable in later life. Symptoms can begin before age 65, usually described as young-onset or early-onset Alzheimer's disease. Population estimates vary with age ranges, definitions and whether they count clinical dementia or biological disease markers.

Those figures should not be used to predict one person's future. A family history can be relevant without making the diagnosis certain, and many affected people do not have an obvious pattern of the disease across generations.

Assessment in the United Kingdom

The NHS approach starts with a GP review of symptoms, health, medicines and possible alternatives. Specialist assessment may combine cognitive testing, history from the person and someone who knows them, and brain imaging. Education and literacy affect test performance: an isolated score cannot confirm or exclude Alzheimer's disease.

UK terminology and care context

Alzheimer's disease is a cause of cognitive impairment and dementia, not a synonym for all memory loss. The UK assessment pathway examines alternative and coexisting causes. Discussion of newer biological tests or treatments must distinguish a research finding, an authorised product indication and what a particular NHS service currently offers.

Signs and Symptoms

Common changes include repeating questions, forgetting recent conversations, struggling with familiar tasks or becoming disoriented in familiar places. Language, planning, judgement and visual understanding can also be affected. The pattern varies, and memory loss is not always the first complaint.

As difficulties progress, support may be needed with medicines, meals, personal care and communication. A sudden change over hours or days is not the usual gradual pattern and requires emergency medical care now to assess for another problem. New neurological symptoms during disease-targeted treatment also require immediate attention rather than being attributed to Alzheimer's progression.

What Causes It?

Researchers understand several important features of the disease but not a single complete explanation for every case. Age, inherited factors and other biological and health influences contribute to risk. Some uncommon inherited forms differ from the more usual pattern seen later in life.

The presence of a risk factor does not prove that disease will develop, and its absence does not rule it out. Vascular disease can coexist and add to cognitive difficulties. Alzheimer's disease is not caused by a lack of effort, poor character or a family member failing to provide enough mental stimulation.

What Do We Know About the Brain?

Alzheimer's disease involves changes in brain cells and their connections, with amyloid plaques and tau tangles among its characteristic findings. These changes affect networks involved in memory and other thinking abilities. The relationship between biological changes and everyday symptoms is complex, and more than one brain disease may be present.

Tests can sometimes detect disease-related changes before substantial functional impairment, but a biological finding does not describe everything about the person. Research into these processes guides new treatments; it does not justify promises that removing one abnormal protein will reverse all effects of the disease.

Conditions With Similar Symptoms

Normal ageing, mild cognitive impairment from other causes, vascular cognitive impairment, dementia with Lewy bodies and frontotemporal disorders can produce overlapping concerns. Depression, sleep problems, medicine effects and other medical illnesses may also affect thinking. Delirium is particularly important when changes are sudden or fluctuate markedly.

Alzheimer's disease and another condition can occur together, so assessment is not always a choice between two mutually exclusive labels. The timing and pattern of symptoms, examination and targeted tests help distinguish the possibilities. One forgotten appointment or a single screening result is not enough to determine the cause.

Other Conditions That Can Occur Together

People may also experience depression, anxiety, sleep disturbance, pain or sensory difficulties. Other brain changes, including vascular or Lewy body disease, may contribute to a mixed clinical picture. Physical illnesses still need ordinary medical attention rather than being overlooked because a dementia diagnosis is present.

Behavioural changes can reflect discomfort or difficulty communicating needs. Care partners may face substantial emotional and practical strain. Care should therefore include the person's wider health and the wellbeing of those providing support, not only a medication decision or repeated testing of memory.

What to Expect Over Time

Alzheimer's disease generally progresses, but the pace and pattern vary. Some abilities may remain useful long after difficulties appear in others. Treatments can have limited and variable benefits, and a slower average decline in a trial does not guarantee the same outcome for an individual.

Plans should be adjusted as communication, mobility and self-care needs change. New symptoms deserve assessment rather than automatic attribution to the underlying disease. Support can continue to improve comfort, dignity and participation even when the illness is advancing, and care goals may shift over time.

Everyday Life and Support

Daily life often works best when support is simple, familiar and respectful. Allow extra time, use clear language and avoid repeatedly correcting minor mistakes that do not affect safety. Review concerns about driving, cooking, medicines and money management with appropriate professionals.

Keep enjoyable activities and relationships available in adapted forms. A written care plan can help family members coordinate responsibilities and recognise changes from the person's usual state. Care partners need breaks and their own medical care. Asking for more help is a response to changing needs, not evidence of failure or lack of commitment.

Treatment and support in the United Kingdom

Support is not limited to medicines. Cognitive stimulation, personally meaningful rehabilitation goals, and reminiscence or life-story work may help day-to-day functioning and wellbeing. Plans should include carers and adapt as needs change. A diagnosis can prompt discussion of future healthcare and practical arrangements without assuming identical legal processes across the four nations.

Can medication help?

Donepezil, galantamine and rivastigmine are established symptom treatments; memantine has a role in moderate or severe disease according to clinical circumstances. They do not cure Alzheimer's disease. Separately, MHRA authorised lecanemab and donanemab in 2024 for restricted early-Alzheimer's populations with one or no APOE4 copies.

These anti-amyloid treatments can cause brain swelling or bleeding and need specialist eligibility and safety monitoring. Authorisation does not establish NHS funding. The checked NICE project records describe ongoing appraisal/appeal work, not a final blanket access recommendation.

History

The disease is named after Alois Alzheimer, who described distinctive brain changes in 1906 after caring for a woman with difficulties involving memory, language and behaviour. The deposits now called amyloid plaques and tau tangles became central to its study.

Later research showed that similar processes could affect older adults, not only unusually young patients. For many years, care focused mainly on symptom management and support. More recent research has added biological tests and disease-targeted medicines for selected early-stage patients.

This is progress, but it does not mean that a positive test predicts an exact course or that treatment restores lost abilities. Clinical care still depends on function, safety, preferences and support.

Sources and References

  1. Sudden confusion (delirium)

    Scope: International scientific/background source; no UK prescribing or service applicability inferred.

  2. Signs and Symptoms of Stroke

    Scope: International scientific/background source; no UK prescribing or service applicability inferred.

  3. Alzheimer's Disease Fact Sheet

    Scope: International scientific/background source; no UK prescribing or service applicability inferred.

  4. Alzheimer's Disease

    Scope: International scientific/background source; no UK prescribing or service applicability inferred.

  5. Clinical descriptions and diagnostic requirements for ICD-11: dementia due to Alzheimer disease, pages 621–623

    Scope: International scientific/background source; no UK prescribing or service applicability inferred.

  6. Alzheimer's disease: diagnosis

    Scope: England; NHS patient information.

  7. Alzheimer's disease: treatment

    Scope: England; NHS patient information.

  8. Lecanemab licensed for adult patients in the early stages of Alzheimer's disease

    Scope: Great Britain authorisation announcement in 2024; not proof of NHS access.

  9. Donanemab licensed for early stages of Alzheimer's disease in adult patients who have one or no copies of apolipoprotein E4 gene

    Scope: UK medicines regulator; authorisation announcement not NHS funding.

  10. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]: project information

    Scope: NICE technology appraisal process; not a UK-wide access entitlement.

  11. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]: project information

    Scope: NICE technology appraisal process; not a UK-wide access entitlement.

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top